Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;14(9):1255-75.

Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy

Yuan-qiang Zheng  1 , Youssef W Naguib, Yixuan Dong, Yan-chun Shi, Shorgan Bou, Zhengrong Cui
Affiliations
Review

Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy

Yuan-qiang Zheng et al. Expert Rev Vaccines. 2015.

Abstract

Bacillus Calmette-Guerin (BCG) vaccines are attenuated live strains of Mycobacterium bovis and are among the most widely used vaccines in the world. BCG is proven to be effective in preventing severe infant meningitis and miliary tuberculosis. Intravesical instillation of BCG is also a standard treatment for non-muscle invasive bladder cancer. In the past few decades, recombinant BCG (rBCG) technology had been extensively applied to develop vaccine candidates for a variety of infectious diseases, including bacterial, viral, and parasite infections, and to improve the efficacy of BCG in bladder cancer therapy. This review is intended to show the vast applications of BCG and recombinant BCG (rBCG) in the prevention of infectious diseases and cancer immunotherapy, with a special emphasis on recent approaches and trends on both pre-clinical and clinical levels.

Keywords: Bacillus Calmette-Guerin; bacterial vector; bladder cancer; clinical applications; infectious disease; recombinant BCG; tumor; vaccine development.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors have no conflict of interest to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Milstien J. Expanded Programme on Immunization. Module 5: Tuberculosis. The Immunological Basis for Immunization Series. 1993;93.15:1–12.
    1. Ahn JJ, McKiernan JM. New agents for bacillus Calmette-Guerin-refractory bladder cancer. Urol Clin North Am. 2013;40(2):219–232. - PubMed
    1. Kremer L, Dupre L, Riveau G, Capron A, Locht C. Systemic and mucosal immune responses after intranasal administration of recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing glutathione S-transferase from Schistosoma haematobium. Infect Immun. 1998;66(12):5669–5676. - PMC - PubMed
    1. Kawahara M, Hashimoto A, Toida I, Honda M. Oral recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity. Clin Immunol. 2002;105(3):326–331. - PubMed
    1. Kawahara M, Matsuo K, Nakasone T, Hiroi T, Kiyono H, Matsumoto S, et al. Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen. Vaccine. 2002;21(3–4):158–166. - PubMed

Publication types

MeSH terms

LinkOut - more resources